ORGO — Organogenesis Holdings Share News
0.000.00%
Last trade - 00:00- $127.80m
- $85.28m
- $564.17m
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers
Brief: FDA Accepts Organogenesis' Biologics License Application For Renu
Organogenesis Q1 revenue misses estimates on lower wound care sales
Brief: Organogenesis Q1 Net Product Revenue USD 36.3 Million
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom
Organogenesis jumps after FDA clears path for knee pain drug filing
Brief: Organogenesis Announces Successful FDA Meeting And Plan To File BLA For Renu® For Knee Osteoarthritis Pain
Organogenesis Q4 net product revenue jumps 78% on wound care growth
Brief: Organogenesis Q4 Net Product Revenue USD 225.1 Million
Brief: Organogenesis Announces Successful FDA Meeting And Plan To File BLA For Renu®
U.S. STOCKS ON THE MOVE-Akamai Technologies, Enbridge, KKR
Organogenesis rises as Q3 revenue beats estimates
Regenerative medicine maker Organogenesis beats Q3 revenue estimates on rise in advanced wound care products